SCHEMBL24309874

SCHEMBL24309874

CN(c1nc(Oc2ccccc2)cc(-c2ccccc2)n1)S(=O)(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ CYP1A2 P05177 3/20 0.44
▸ CYP2C9 P11712 3/20 0.44
▸ CYP2C19 P33261 3/20 0.44
▸ ATM Q13315 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ PGR P06401 4/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ FFAR1 O14842 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309876 0.74 MAPK1 (0.55) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL14507076 0.74 IKBKB (0.46) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL26806813 0.73 MAPT (0.61) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL24310603 0.71 MAPT (0.47) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL11978702 0.70 MAPK1 (0.70) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL14987893 0.70 MAPK1 (1.00) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL24310185 0.69 PGR (0.58) MAPK1TDP1MAPTPGRSMN1; SMN2
SCHEMBL26812980 0.69 MAPT (0.50) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL26812990 0.68 TDP1 (0.54) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL26812998 0.68 TDP1 (0.54) MAPK1TDP1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPK1 3810/4885TDP1 4534/4885MEN1 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback